Bristol-myers Drug Patent Portfolio

Bristol-myers owns 4 orange book drugs protected by 60 US patents Given below is the list of Bristol-myers's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11400092 Methods of treating myeloproliferative disorders 24 Sep, 2039
Active
US9511046 Methods of treating pancreatic cancer 12 Jul, 2034
Active
US9511046 Methods of treating pancreatic cancer 12 Jan, 2034
Active
US9393318 Methods of treating cancer 04 Sep, 2032
Active
US9597409 Methods of treating cancer 04 Sep, 2032
Active
US10391094 Compositions and methods for treating myelofibrosis 04 Jun, 2032
Active
US9393318 Methods of treating cancer 04 Mar, 2032
Active
US9597409 Methods of treating cancer 04 Mar, 2032
Active
US7528143 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Nov, 2031
Active
US8138199 Use of bi-aryl meta-pyrimidine inhibitors of kinases 30 Jun, 2028
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Feb, 2027
Active
US7825246 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Dec, 2026
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Aug, 2026
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
Active
US7820788 Compositions and methods of delivery of pharmacological agents 27 Apr, 2025
Active
US7820788 Compositions and methods of delivery of pharmacological agents 27 Oct, 2024
Active
US7923536 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Jun, 2024 Expired
US7923536 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023 Expired
US7230012 Pharmaceutical compositions and dosage forms of thalidomide 09 Dec, 2023 Expired
US7608280 Method of producing FR901228 22 Aug, 2021 Expired
US7611724 Method of producing FR901228 22 Aug, 2021 Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Apr, 2021 Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020 Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6869399 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7141018 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7959566 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Oct, 2020 Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US7874984 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US7435745 Methods and compositions for inhibition of angiogenesis 03 Nov, 2017 Expired
USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions 14 Aug, 2016 Expired
US5629327 Methods and compositions for inhibition of angiogenesis 13 May, 2014 Expired
US4977138 FR901228 substance and preparation thereof 22 Aug, 2013 Expired
US5498421 Composition useful for in vivo delivery of biologics and methods employing same 12 Mar, 2013 Expired
US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide 01 Mar, 2013 Expired
US7723361 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide 01 Mar, 2013 Expired
US8143283 Methods for treating blood-born tumors with thalidomide 01 Mar, 2013 Expired
US5439686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor 22 Feb, 2013 Expired
US6096331 Methods and compositions useful for administration of chemotherapeutic agents 22 Feb, 2013 Expired
US6506405 Methods and formulations of cremophor-free taxanes 22 Feb, 2013 Expired
US6537579 Compositions and methods for administration of pharmacologically active compounds 22 Feb, 2013 Expired
US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 22 Feb, 2013 Expired
US6753006 Paclitaxel-containing formulations 22 Feb, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Bristol-myers.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 08 Jul, 2024 US8314156 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9511046
Payment of Maintenance Fee, 12th Year, Large Entity 06 Mar, 2024 US8268348 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jan, 2024 US9393318
Payment of Maintenance Fee, 12th Year, Large Entity 06 Sep, 2023 US8138199
Payment of Maintenance Fee, 12th Year, Large Entity 06 Sep, 2023 US8138229 (Litigated)
Expire Patent 17 Jul, 2023 US7959566
Patent Term Extension Certificate 25 May, 2023 US7528143
Payment of Maintenance Fee, 12th Year, Large Entity 29 Mar, 2023 US8034375
Withdrawal of Application for PTE 27 Feb, 2023 US8138199
Withdrawal of Application for PTE 27 Feb, 2023 US7825246
Expire Patent 27 Feb, 2023 US7874984
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2023 US10391094
Maintenance Fee Reminder Mailed 30 Jan, 2023 US7959566
Payment of Maintenance Fee, 8th Year, Large Entity 25 Jan, 2023 US9101543


Bristol-myers's Drug Patent Litigations

Bristol-myers's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2015, against patent number US6315720. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol-myers's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7820788 November, 2017 Terminated-Settled
(13 Jul, 2018)
Abraxis BioScience, LLC Apotex Inc.
US7923536 November, 2017 Terminated-Settled
(13 Jul, 2018)
Abraxis Biosciences, LLC Apotex Inc.
US8138229 November, 2017 Terminated
(13 Jul, 2018)
Abraxis BioScience, LLC et al. Apotex Inc. et al.
US7820788 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US7820788 November, 2017 Terminated-Denied
(08 May, 2018)
Abraxis Biosciences, LLC Cipla Ltd.
US7923536 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US7923536 November, 2017 Terminated-Denied
(08 May, 2018)
Abraxis Biosciences, LLC Cipla Ltd.
US8138229 April, 2017 Terminated-Settled
(08 May, 2018)
ABRAXIS BIOSCIENCE, LLC, Actavis LLC
US8138229 November, 2017 Terminated-Denied
(08 May, 2018)
AbraxisBiosciences, LLC Cipla Ltd.
US8853260 April, 2017 Terminated-Denied
(11 Oct, 2017)
ABRAXIS BIOSCIENCE, LLC Actavis LLC
US6045501 April, 2015 Final Written Decision
(26 Oct, 2016)
Celgene Corporation Coalition For Affordable Drugs VI LLC
US6315720 April, 2015 FWD Entered
(26 Oct, 2016)
Celgene Corporation Coalition for Affordable Drugs VI LLC


Bristol-myers Drug Patents' Oppositions Filed in EPO

Bristol-myers drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 01, 2012, by Generics [Uk] Limited. This opposition was filed on patent number EP06735710A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP14737791A Feb, 2022 Accord Healthcare Revoked
EP14737791A Feb, 2022 Teva Pharmaceutical Industries Ltd. Revoked
EP14737791A Jan, 2022 Generics [UK] Limited Revoked
EP17165979A Apr, 2020 Generics (UK) Ltd Revoked
EP17165979A Apr, 2020 Teva Pharmaceutical Industries Ltd Revoked
EP03799876A Mar, 2019 Teva Pharmaceutical Industries Ltd Revoked
EP03799876A Mar, 2019 Wittkopp, Alexander Revoked
EP11763292A Jun, 2017 Generics (UK) Ltd Revoked
EP11763292A Jun, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP06735710A Aug, 2012 MediGene Aktiengesellschaft Revoked
EP06735710A Aug, 2012 Generics [UK] Limited Revoked


Bristol-myers's Family Patents

Bristol-myers drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 20.1% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Bristol-myers Drug List

Given below is the complete list of Bristol-myers's drugs and the patents protecting them.


1. Abraxane

Abraxane is protected by 32 patents, out of which 16 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9511046
(Pediatric)
Methods of treating pancreatic cancer 12 Jul, 2034
(9 years from now)
Active
US9511046 Methods of treating pancreatic cancer 12 Jan, 2034
(9 years from now)
Active
US9393318
(Pediatric)
Methods of treating cancer 04 Sep, 2032
(7 years from now)
Active
US9597409
(Pediatric)
Methods of treating cancer 04 Sep, 2032
(7 years from now)
Active
US9393318 Methods of treating cancer 04 Mar, 2032
(7 years from now)
Active
US9597409 Methods of treating cancer 04 Mar, 2032
(7 years from now)
Active
US8034375
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 13 Feb, 2027
(2 years from now)
Active
US7758891
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(1 year, 10 months from now)
Active
US8268348
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(1 year, 10 months from now)
Active
US9101543
(Pediatric)
Combinations and modes of administration of therapeutic agents and combination therapy 21 Aug, 2026
(1 year, 10 months from now)
Active
US8034375 Combinations and modes of administration of therapeutic agents and combination therapy 13 Aug, 2026
(1 year, 9 months from now)
Active
US7758891 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(1 year, 4 months from now)
Active
US8268348 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(1 year, 4 months from now)
Active
US9101543 Combinations and modes of administration of therapeutic agents and combination therapy 21 Feb, 2026
(1 year, 4 months from now)
Active
US7820788
(Pediatric)
Compositions and methods of delivery of pharmacological agents 27 Apr, 2025
(6 months from now)
Active
US7820788 Compositions and methods of delivery of pharmacological agents 27 Oct, 2024
(12 days from now)
Active
US7923536
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(4 months ago)
Expired
US8138229
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(4 months ago)
Expired
US8314156
(Pediatric)
Compositions and methods of delivery of pharmacological agents 09 Jun, 2024
(4 months ago)
Expired
US7923536 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(10 months ago)
Expired
US8138229 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(10 months ago)
Expired
US8314156 Compositions and methods of delivery of pharmacological agents 09 Dec, 2023
(10 months ago)
Expired
US8853260
(Pediatric)
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Apr, 2021
(3 years ago)
Expired
US8853260 Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof 10 Oct, 2020
(4 years ago)
Expired
USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions 14 Aug, 2016
(8 years ago)
Expired
US5498421 Composition useful for in vivo delivery of biologics and methods employing same 12 Mar, 2013
(11 years ago)
Expired
US5439686 Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor 22 Feb, 2013
(11 years ago)
Expired
US6096331 Methods and compositions useful for administration of chemotherapeutic agents 22 Feb, 2013
(11 years ago)
Expired
US6506405 Methods and formulations of cremophor-free taxanes 22 Feb, 2013
(11 years ago)
Expired
US6537579 Compositions and methods for administration of pharmacologically active compounds 22 Feb, 2013
(11 years ago)
Expired
US6749868 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof 22 Feb, 2013
(11 years ago)
Expired
US6753006 Paclitaxel-containing formulations 22 Feb, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abraxane's drug page


2. Inrebic

Inrebic is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11400092 Methods of treating myeloproliferative disorders 24 Sep, 2039
(14 years from now)
Active
US10391094 Compositions and methods for treating myelofibrosis 04 Jun, 2032
(7 years from now)
Active
US7528143 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Nov, 2031
(7 years from now)
Active
US8138199 Use of bi-aryl meta-pyrimidine inhibitors of kinases 30 Jun, 2028
(3 years from now)
Active
US7825246 Bi-aryl meta-pyrimidine inhibitors of kinases 16 Dec, 2026
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inrebic's drug page


3. Istodax

Istodax is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7608280 Method of producing FR901228 22 Aug, 2021
(3 years ago)
Expired
US7611724 Method of producing FR901228 22 Aug, 2021
(3 years ago)
Expired
US4977138 FR901228 substance and preparation thereof 22 Aug, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Istodax's drug page


4. Thalomid

Thalomid is protected by 20 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7230012 Pharmaceutical compositions and dosage forms of thalidomide 09 Dec, 2023
(10 months ago)
Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020
(3 years ago)
Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US6869399 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US7141018 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US7959566 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(3 years ago)
Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US7874984 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US7435745 Methods and compositions for inhibition of angiogenesis 03 Nov, 2017
(6 years ago)
Expired
US5629327 Methods and compositions for inhibition of angiogenesis 13 May, 2014
(10 years ago)
Expired
US6235756 Methods and compositions for inhibition of angiogenesis by thalidomide 01 Mar, 2013
(11 years ago)
Expired
US7723361 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide 01 Mar, 2013
(11 years ago)
Expired
US8143283 Methods for treating blood-born tumors with thalidomide 01 Mar, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thalomid's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List